葵花SUNFLOWER品牌怎么样 申请店铺

我要投票 葵花SUNFLOWER在医疗保健行业中的票数:1000 更新时间:2026-01-24
葵花SUNFLOWER是哪个国家的品牌?「葵花SUNFLOWER」是 葵花药业集团股份有限公司 旗下著名品牌。该品牌发源于黑龙江哈尔滨市,由创始人关玉秀在2005-09-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力葵花SUNFLOWER品牌出海!将品牌入驻外推网,定制葵花SUNFLOWER品牌推广信息,可以显著提高葵花SUNFLOWER产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

葵花SUNFLOWER怎么样

黑龙江葵花药业集团有限公司,黑龙江名牌,以胃康灵为代表的胃肠用药和小儿肺热咳喘口服液为代表的儿童用药著称


葵花药业集团是以中成药为主,以化学药、生物药、补益保健类产品为辅,集药品制造、营销、科研于一体的大型民营医药企业集团。现拥有五常葵花、伊春葵花、佳木斯葵花、佳木斯(鹿灵)葵花、唐山葵花、衡水葵花、冀州葵花、重庆葵花、隆中葵花、武当葵花、临江葵花、贵州葵花等12家药品生产企业,4家医药公司,1个药物研究院,1个药材种植基地,1个药品包材公司等23家子公司。2014年,在深圳证券交易所成功上市(股票代码:002737)。

在产品布局上,由改制初期的一个产品打天下,现发展为拥有15个剂型、1132个药品批准文号,其中,有29个品种、566个医保目录品种、274个基本药物品种,形成了儿科、妇科、消化系统、呼吸感冒、风湿骨伤病和心脑血管慢病6大特色产品集群,完成了从品种到品牌、再到品类的转化。

在科技研发上,葵花曾成功研发出以护肝片、胃康灵胶囊为代表的全国知名中药产品,为我国中药事业的发展做出了突出贡献。现在北京和哈尔滨分别设立了药物研究院,在各企业均设立了科研所,专注于中药、天然药物、化药的研究开发,通过“买、改、联、研”的研发战略,来不断提高企业创新发展能力。


Heilongjiang sunflower Pharmaceutical Group Co., Ltd., a famous brand in Heilongjiang Province, is famous for gastrointestinal medicine represented by Weikangling and children's lung heat cough and asthma oral liquid. Sunflower Pharmaceutical Group is a large-scale private pharmaceutical enterprise group mainly composed of proprietary Chinese medicine, supplemented by chemical medicine, biological medicine, tonic and health care products, integrating drug manufacturing, marketing and scientific research. Now it has 12 pharmaceutical manufacturers, 4 pharmaceutical companies, 1 Pharmaceutical Research Institute, 1 pharmaceutical planting base, 1 pharmaceutical packaging company and 23 subsidiaries, including Wuchang sunflower, Yichun sunflower, Jiamusi sunflower, Jiamusi (Luling) sunflower, Tangshan sunflower, Hengshui sunflower, Jizhou sunflower, Chongqing sunflower, Longzhong sunflower, Wudang sunflower, Linjiang sunflower and Guizhou sunflower. In 2014, it was successfully listed on Shenzhen Stock Exchange (Stock Code: 002737). In terms of product layout, it has developed from a product in the early stage of restructuring to a product with 15 dosage forms and 1132 drug approval numbers, including 29 varieties, 566 medical insurance catalog varieties and 274 basic drug varieties, forming 6 characteristic product clusters of Pediatrics, gynecology, digestive system, respiratory, rheumatism and osteopathy, and chronic cardiovascular and cerebrovascular diseases, completing the transformation from varieties to brands , and then to category transformation. In terms of scientific and technological research and development, sunflower has successfully developed national famous traditional Chinese medicine products represented by Hugan tablet and Weikangling capsule, which has made outstanding contributions to the development of traditional Chinese medicine in China. Now, Beijing and Harbin have set up drug research institutes respectively, and scientific research institutes have been set up in all enterprises, focusing on the research and development of traditional Chinese medicine, natural medicine and chemical medicine. Through the R & D strategy of "purchase, reform, joint research and development", the innovation and development ability of enterprises has been continuously improved.

本文链接: https://brand.waitui.com/49cab8429.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前涨跌不一,Arm涨超2%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,Arm涨超2%,英伟达涨超1%,谷歌涨0.1%,微软涨0.06%;特斯拉跌0.17%,奈飞跌0.11%,亚马逊跌0.07%,苹果跌0.03%。

50分钟前

热门中概股美股盘前涨跌互现,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前涨跌互现,截至发稿,阿里巴巴、京东跌超1%,小鹏汽车跌近1%,网易跌0.48%,蔚来跌0.21%;百度涨超1%,拼多多涨0.75%,理想汽车涨0.42%,B站涨0.09%。

50分钟前

晶升股份:拟购买为准智能100%股份,交易作价8.57亿元

36氪获悉,晶升股份公告,公司拟通过发行股份及支付现金的方式购买本尚科技等10名交易对方持有的为准智能100%股份,同时募集配套资金。为准智能100%股份的交易作价为8.57亿元。本次交易构成关联交易和重大资产重组,但不构成重组上市。交易完成后,为准智能将成为上市公司控股子公司。

50分钟前

天合光能:将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”

36氪获悉,天合光能公告,公司拟缩减“年产35GW直拉单晶项目”的募集资金投资金额,不再实施二期15GW项目,并将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”。新项目预计2026年底建成并投入运营。公司表示,本次变更有利于提高募集资金使用效率,合理优化资源配置,巩固市场地位,不会对公司正常经营产生不利影响。该事项尚需提交公司股东会和债券持有人会议审议通过后方可实施。

50分钟前

宝洁第二财季净销售额222亿美元,同比增长1%

当地时间1月22日,宝洁公司发布2026财年第二季度(2025年10-12月)财报。财报显示,第二财季净销售额为222亿美元,同比增长1%;摊薄后每股净收益为1.78美元,同比下降5%。该公司维持2026财年总销售额同比增长1%至5%的指引区间,将2026财年摊薄后每股净收益增长指引从原先的3%-9%调整至1%-6%。(界面)

50分钟前

本页详细列出关于葵花SUNFLOWER的品牌信息,含品牌所属公司介绍,葵花SUNFLOWER所处行业的品牌地位及优势。
咨询